MedTrace Logo

MB-CART20.1 Lymphoma

NCT03664635 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-11-21

No results posted yet for this study

Summary

This trial is a phase I/II trial to assess safety, dose finding and feasibility of ex vivo generated MB-CART20.1 cells in patients with relapsed or refractory CD20 positive B-NHL.

Conditions

  • Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
  • Non-Hodgkin's Lymphoma
  • B-cell Lymphoma Refractory
  • B-cell Lymphoma Recurrent

Interventions

BIOLOGICAL

MB-CART20.1

MB-CART20.1 consists of autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4 /CD8 enriched T cells targeting CD20-positive tumor cells in NHL

Sponsors & Collaborators

  • Miltenyi Biomedicine GmbH

    lead INDUSTRY

Principal Investigators

  • Peter Borchmann, Prof. Dr. · Universitätsklinikum Köln

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-25
Primary Completion
2024-09-17
Completion
2024-09-17

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03664635 on ClinicalTrials.gov